Literature DB >> 12519218

Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population.

Reza Malekzadeh1, Shahin Merat, Mohammad-Hassan Derakhshan, Farideh Siavoshi, Abbas Yazdanbod, Javad Mikaeli, Rasoul Sotoudemanesh, Masoud Sotoudeh, Mohammad-Jafar Farahvash, Siavosh Nasseri-Moghaddam, Akram Pourshams, Shahab Dolatshahi, Behnoosh Abedi, Masoud Babaei, Shahnam Arshi, Ali Majidpour.   

Abstract

BACKGROUND: In Iran, there is insufficient information on the efficacy of Helicobacter pylori eradication regimens shorter than 10 days. This study aims at assessing the efficacy of 4- and 7-day H. pylori eradication regimens in a high-incidence area of gastric cancer in Iran.
METHODS: Subjects with an endoscopic diagnosis of gastritis, positive urease test, and a histological diagnosis of chronic gastritis were enrolled. Patients were randomly assigned to one of three groups: AOC7 (1000 mg amoxicillin, 20 mg omeprazole, and 500 mg clarithromycin twice daily for 7 days), FOT4 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 4 days) and FOT7 (the same treatment as the FOT4 group but for 7 days). Sensitivity to these antibiotics was determined in all isolates recovered from culture. The efficacy of eradication was assessed 8 weeks after the end-of-treatment by the 14C-urea breath test.
RESULTS: One hundred and twenty-eight patients were enrolled in the study. Culture was positive for 84 patients and none of these were resistant to amoxicillin, tetracycline or furazolidone, 1.2% were resistant to clarithromycin and 32.1% to metronidazole. Forty-five, 41 and 42 patients were randomly allocated to the AOC7, FOT4, and FOT7 groups, respectively. The intention-to-treat eradication rates were 35.5, 17.1, and 23.8% for the AOC7, FOT4, and FOT7 groups, respectively.
CONCLUSION: Treatment regimens of 4 or 7 days are unacceptable for H. pylori infection in Iran, even in the presence of a favorable sensitivity profile. Copyright 2003 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519218     DOI: 10.1046/j.1440-1746.2003.02897.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  14 in total

1.  Azithromycin in one week quadruple therapy for H pylori eradication in Iran.

Authors:  Shahrokh Mousavi; Jafar Toussy; Siamak Yaghmaie; Mehrdad Zahmatkesh
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

2.  Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.

Authors:  Seyed Amir Mirbagheri; Mehrdad Hasibi; Mehdi Abouzari; Armin Rashidi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

3.  Helicobacter pylori antibiotic resistance in Iran.

Authors:  Marjan Mohammadi; Delaram Doroud; Nazanin Mohajerani; Sadegh Massarrat
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

4.  Helicobacter pylori endemic and gastric disease.

Authors:  Farideh Siavoshi; Reza Malekzadeh; Mohammad Daneshmand; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

Review 5.  Helicobacter pylori eradication in West Asia: a review.

Authors:  Hafez Fakheri; Zohreh Bari; Mohsen Aarabi; Reza Malekzadeh
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

6.  Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian population.

Authors:  Ali-Asghar Keshavarz; Homayoon Bashiri; Mahtab Rahbar
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 7.  Is short-term therapy really sufficient to eradicate Helicobacter pylori infection?

Authors:  Ning Zhou; Wei-xing Chen; Wei Zhang; Lan Li; Xi Jin; You-ming Li
Journal:  J Zhejiang Univ Sci B       Date:  2010-09       Impact factor: 3.066

8.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

Review 9.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

10.  Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.

Authors:  Salman R Hasan; Vahabzadeh Vahid; Pahlvanzadah M Reza; Salman R Roham
Journal:  Saudi J Gastroenterol       Date:  2010 Jan-Mar       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.